colorectal cancer

Comprehensive framework outlined for addressing early-onset colorectal cancer research

New research from Vanderbilt sets a comprehensive framework for addressing research challenges and patient needs for people under 50 with colorectal cancer.

From left, Ken Lau, PhD, Bob Chen, Qi Liu, PhD, Joseph Rolland, PhD, Martha Shrubsole, PhD, Robert Coffey, MD, and colleagues are studying how polyps develop into colorectal cancer, setting the framework for improved surveillance for the cancer utilizing precision medicine. (photo by Erin O. Smith)

Study sets framework for precision surveillance of colorectal cancer

Vanderbilt research has revealed some of the mechanisms by which polyps develop into colorectal cancer, setting the framework for improved surveillance for the cancer utilizing precision medicine.

Ayaka Sugiura and Jeff Rathmell, PhD, are studying a metabolic enzyme involved in T cell function that may offer a new target for anti-inflammatory therapeutics.

CRISPR screen identifies new anti-inflammatory drug target

A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics.

People at high genetic risk for colorectal cancer benefit more from lifestyle changes

People with a high polygenic risk score for colorectal cancer could benefit more at preventing the disease by leading healthy lifestyles than those at lower genetic risk, according to a study by Vanderbilt researchers published in the April issue of The American Journal of Clinical Nutrition.

Chemo for cancer lowers dementia risk

Cancer chemotherapy lowered risk of Alzheimer’s disease and other neurocognitive disorders that disproportionately affect older people.

Vitamin D activation and cancer risk

Vitamin D protection against colon cancer varies according to parathyroid hormone response, particularly among women.

1 2 3 4 6